Exclusive rights to universal CAR technology platform designed to target multiple antigens simultaneously, recently expanded to include SNAP-CAR NK cells, has potential to impact various autoimmune diseases in addition to oncology indications.

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced that it has expanded its exclusive license agreement with the University of Pittsburgh to include autoimmune indications as part of its ongoing development of SNAP-CAR T and SNAP-CAR NK.